Ultrasonicated synthesis of 1-(2-hydroxyaryl)-3-(pyrrolidin-1-yl)-prop-2-en-1-ones and their antimicrobial screening

Abstract: A facile synthesis of title compounds has been carried out under ultrasound irradiation. The main advantages of the present procedure are shorter reaction time and higher yield. Products have been characterized by IR, PMR, CMR, GCMS study and screened for their antimicrobial activity

Synthesis and Antimicrobial Evaluation of Novel Carbazole Based β-diketones and its Pyrazole Derivatives

Novel 9-ethyl-9H-carbazole-3-carboxylic acid derivatives including ester, β-diketone and pyrazole were prepared and characterized by FT-IR, 1H NMR, 13C NMR and mass spectroscopic techniques. All synthesized compounds evaluated for their in vitro antimicrobial activities against four bacteria (Escherichia coli, Pseudomonas putide, Bacillus subtilis, and Streptococcus lactis) and three fungi (Aspergillus niger, Penicillium sp and Candida albicans). Among the compounds tested, 3a, 3b, 3c, 4a, 4b, 4c, 5a and 5b exhibited pronounced antibacterial activity as compared with standard drug ampicillin. Notably, carbazole based pyrazole derivatives 5a and 5b showed potent antifungal activity against C. albicans comparable to reference drug greseofulvin. This work is licensed under a Creative Commons Attribution 4.0 International License

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly

Synthesis and Evaluation of Novel 1, 5- Benzothiazepine Derivatives as Anti- Inflammatory Agents

ABSTRACT:Novel 1, 5-benzothiazepine derivatives were synthesized and characterized by spectral studies. The newly synthesized compounds (4a-g) were screened for in vivo anti-inflammatory activity at a dose of 10 mg/kg BW. Among those tested, compounds 4c, 4d and 4g exhibited significant anti-inflammatory activity in models of acute inflammation such as rat paw edema, while compounds 4c and 4g showed considerable activity compared with diclofenac as a standard drug

Iron Oxide-Cobalt Nanocatalyst for O-tert-Boc Protection and O-Arylation of Phenols

Efficient and general protocols for the O-tert-boc protection and O-arylation of phenols were developed in this paper using a recyclable magnetic Fe3O4-Co3O4 nanocatalyst (Nano-Fe-Co), which is easily accessible via simple wet impregnation techniques in aqueous mediums from inexpensive precursors. The results showed the catalysts were well characterized by XRD (X-ray Diffraction), ICP-AES (Inductive Coupled Plasma Atomic Emission Spectroscopy), TEM (Transmission Electron Microscopy), TOF-SIMS (Time-Of-Flight Secondary Ion Mass Spectrometry) and XPS (X-ray Photoelectron Spectroscopy). The O-tert-boc protection and O-arylation of phenols was accomplished in good to excellent yields (85–95%) and the catalyst was reusable and recyclable with no loss of catalytic activity for at least six repetitions

Iron-Oxide-Supported Ultrasmall ZnO Nanoparticles: Applications for Transesterification, Amidation, and O‑Acylation Reactions

An efficient maghemite–ZnO nanocatalyst has been synthesized via a simple coprecipitation method, where ZnO nanoparticles are uniformly decorated on the maghemite core and characterized by XRD, SEM-EDS, ICP-AES, XPS, TEM, HRTEM, and Mössbauer spectroscopy; maghemite nanoparticles are in the typical size range 10–30 nm with ultrasmall (3–5 nm) ZnO nanoparticles. A competent and benign protocol is reported for various organic transformations, namely, transesterification, amidation, and O-acylation reaction in good to excellent yields (75–97%) using magnetically separable and reusable maghemite–ZnO nanocatalyst

Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads.

BACKGROUND Adoption and outcomes for conduction system pacing (CSP), which includes His bundle pacing (HBP) or left bundle branch area pacing (LBBAP), in real-world settings are incompletely understood. We sought to describe real-world adoption of CSP lead implantation and subsequent outcomes. METHODS We performed an online cross-sectional survey on the implantation and outcomes associated with CSP, between November 15, 2020, and February 15, 2021. We described survey responses and reported HBP and LBBAP outcomes for bradycardia pacing and cardiac resynchronization CRT indications, separately. RESULTS The analysis cohort included 140 institutions, located on 5 continents, who contributed data to the worldwide survey on CSP. Of these, 127 institutions (90.7%) reported experience implanting CSP leads. CSP and overall device implantation volumes were reported by 84 institutions. In 2019, the median proportion of device implants with CSP, HBP, and/or LBBAP leads attempted were 4.4% (interquartile range [IQR], 1.9-12.5%; range, 0.4-100%), 3.3% (IQR, 1.3-7.1%; range, 0.2-87.0%), and 2.5% (IQR, 0.5-24.0%; range, 0.1-55.6%), respectively. For bradycardia pacing indications, HBP leads, as compared to LBBAP leads, had higher reported implant threshold (median [IQR]: 1.5 V [1.3-2.0 V] vs 0.8 V [0.6-1.0 V], p = 0.0008) and lower ventricular sensing (median [IQR]: 4.0 mV [3.0-5.0 mV] vs. 10.0 mV [7.0-12.0 mV], p < 0.0001). CONCLUSION In conclusion, CSP lead implantation has been broadly adopted but has yet to become the default approach at most surveyed institutions. As the indications and data for CSP continue to evolve, strategies to educate and promote CSP lead implantation at institutions without CSP lead implantation experience would be necessary